Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Gene Therapy Developments for Pompe Disease
Zeenath Unnisa, John K. Yoon, Jeffrey W. Schindler, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 302-302
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges
Lin Kang, Shilin Jin, Jiayi Wang, et al.
Journal of Controlled Release (2023) Vol. 355, pp. 458-473
Open Access | Times Cited: 64
Chemically Modified Platforms for Better RNA Therapeutics
Yesi Shi, Xueyan Zhen, Yiming Zhang, et al.
Chemical Reviews (2024) Vol. 124, Iss. 3, pp. 929-1033
Closed Access | Times Cited: 51
A Comprehensive Update on Late-Onset Pompe Disease
Beatrice Labella, Stefano Cotti Piccinelli, Barbara Risi, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1279-1279
Open Access | Times Cited: 24
Treatment of infantile-onset Pompe disease in a rat model with muscle-directed AAV gene therapy
Sergio Muñoz, Joan Bertolin, Verónica Jiménez, et al.
Molecular Metabolism (2024) Vol. 81, pp. 101899-101899
Open Access | Times Cited: 7
Beyond Sarcomeric Hypertrophic Cardiomyopathy: How to Diagnose and Manage Phenocopies
Maurizio Pieroni, Michele Ciabatti, Elisa Saletti, et al.
Current Cardiology Reports (2022) Vol. 24, Iss. 11, pp. 1567-1585
Closed Access | Times Cited: 26
Efficacy and safety of enzyme replacement therapy with alglucosidase alfa for the treatment of patients with infantile-onset Pompe disease: a systematic review and metanalysis
Alícia Dorneles Dornelles, Ana Paula Pedroso Junges, Bárbara Krug, et al.
Frontiers in Pediatrics (2024) Vol. 12
Open Access | Times Cited: 6
Using an In Vivo Mouse Model to Determine the Exclusion Criteria of Preexisting Anti-AAV9 Neutralizing Antibody Titer of Pompe Disease Patients in Clinical Trials
Hanqing Wang, Cengceng Zhang, Zheyue Dong, et al.
Viruses (2024) Vol. 16, Iss. 3, pp. 400-400
Open Access | Times Cited: 4
Food and Drug Administration (FDA) Approvals of Biological Drugs in 2023
Alexander C. Martins, Mariana Y. Oshiro, Fernando Alberício, et al.
Biomedicines (2024) Vol. 12, Iss. 9, pp. 1992-1992
Open Access | Times Cited: 4
Targeted miRNA Delivery in Epilepsy: Mechanisms, Advances, and Therapeutic Potential
Mukul Shyam, Oveyaa Bm, Prathap Srirangan, et al.
Molecular Biology Reports (2025) Vol. 52, Iss. 1
Closed Access
Improving the treatment of pompe disease with enzyme replacement therapy: current strategies and clinical evidence
Alberto Corsini
Expert Opinion on Pharmacotherapy (2025)
Closed Access
Muscle‐specific, liver‐detargeted adeno‐associated virus gene therapy rescues Pompe phenotype in adult and neonate Gaa−/− mice
Pauline Sellier, Pierre Vidal, Benjamin Bertin, et al.
Journal of Inherited Metabolic Disease (2023) Vol. 47, Iss. 1, pp. 119-134
Open Access | Times Cited: 8
Chimeric Cell Therapies as a Novel Approach for Duchenne Muscular Dystrophy (DMD) and Muscle Regeneration
Katarzyna Budzynska, Maria Siemionow, Katarzyna Stawarz, et al.
Biomolecules (2024) Vol. 14, Iss. 5, pp. 575-575
Open Access | Times Cited: 3
AAV-mediated delivery of secreted acid α-glucosidase with enhanced uptake corrects neuromuscular pathology in Pompe mice
Naresh Kumar Meena, Davide Randazzo, Nina Raben, et al.
JCI Insight (2023) Vol. 8, Iss. 16
Open Access | Times Cited: 7
Rare genetic disorders in India: Current status, challenges, and CRISPR-based therapy
Pallabi Bhattacharyya, Kanikah Mehndiratta, Souvik Maiti, et al.
Journal of Biosciences (2024) Vol. 49, Iss. 1
Closed Access | Times Cited: 2
PRKAG2‐Related Lethal Congenital Glycogen Storage Disease of the Heart as Rare Cause of Fetal Hydrops With Bradycardia and Cardiomyopathy: Clinical Report and Literature Review
Alexandre White‐Brown, Marilyn Richard, Anne‐Maude Morency, et al.
American Journal of Medical Genetics Part A (2024)
Open Access | Times Cited: 2
Pompe disease: Unmet needs and emerging therapies
Kelly A George, Allyson L. Anding, Arjan van der Flier, et al.
Molecular Genetics and Metabolism (2024) Vol. 143, Iss. 3, pp. 108590-108590
Closed Access | Times Cited: 2
The use of adenoviral vectors in gene therapy and vaccine approaches
Natália Meneses Araújo, Ileana Gabriela Sanchez Rubio, Nicholas Pietro Agulha Toneto, et al.
Genetics and Molecular Biology (2022) Vol. 45, Iss. 3 suppl 1
Open Access | Times Cited: 11
Screening chimeric GAA variants in preclinical study results in hematopoietic stem cell gene therapy candidate vectors for Pompe disease
Yildirim Dogan, Cecilia Barese, Jeffrey W. Schindler, et al.
Molecular Therapy — Methods & Clinical Development (2022) Vol. 27, pp. 464-487
Open Access | Times Cited: 9
Gene and Cellular Therapies for Leukodystrophies
Fatima Aerts‐Kaya, Niek P. van Til
Pharmaceutics (2023) Vol. 15, Iss. 11, pp. 2522-2522
Open Access | Times Cited: 5
Genotypic and phenotypic characteristics of 12 chinese children with glycogen storage diseases
Rui Dong, Xuxia Wei, Kaihui Zhang, et al.
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 8
Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes
Nuria Gómez-Cebrián, Elena Gras‐Colomer, José Luís Poveda Andrés, et al.
Biology (2023) Vol. 12, Iss. 9, pp. 1159-1159
Open Access | Times Cited: 4
Crucial aspects for maintaining rAAV stability
Johannes Lengler, M. G. Gavrila, Janina Brandis, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Therapeutic thoroughfares for adults living with Pompe disease
Benedikt Schoser, Pascal Laforêt
Current Opinion in Neurology (2022)
Closed Access | Times Cited: 6
Molekulare Therapien: Gegenwart und Zukunft bei neuromuskulären Erkrankungen
Andreas Ziegler, Maggie C. Walter, Benedikt E. Schoser
Der Nervenarzt (2023) Vol. 94, Iss. 6, pp. 473-487
Open Access | Times Cited: 3
Towards personalized genome-scale modeling of inborn errors of metabolism for systems medicine applications
Almut Heinken, Sandra El Kouche, Rosa‐Maria Guéant‐Rodriguez, et al.
Metabolism (2023) Vol. 150, pp. 155738-155738
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top